Medical Centers Worldwide Adopt Both Accuray's CyberKnife and TomoTherapy Systems

Provides personalized care to treat the full spectrum of radiation oncology patients

News provided by

Dec 19, 2011, 08:30 ET

SUNNYVALE, Calif., Dec. 19, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that 23 leading medical centers globally have installed both a CyberKnife^® Robotic Radiosurgery System and a TomoTherapy® System enabling the delivery of personalized treatment for the full spectrum of radiation oncology patients. These centers include smaller community sites in rural areas, mid-sized regional hospitals and large academic centers, indicating that centers of all sizes are benefiting from having both CyberKnife and TomoTherapy Systems.

"We now have the ability to design treatments that fit the individual needs of all patients," said Sandra Vermuelen, M.D., executive medical director of the Swedish Radiosurgery Center in Seattle. "The CyberKnife and TomoTherapy Systems are designed to allow clinicians to create specialized treatments with the ability to facilitate a complete range of treatment techniques ranging from static 3D conformal and highly modulated intensity-modulated radiotherapy (IMRT), to stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). Through the use of daily image-guidance, a standard feature for TomoTherapy, and the CyberKnife System's ability to track, detect and automatically correct for tumor and patient movement, we can ensure the most accurate treatment delivery for all patients."

More than half the centers with both systems are in North America including St. John Medical Center in Tulsa, Centre hospitalier de l'Universite de Montreal (CHUM) and Swedish Medical Center in Seattle. Recent centers in other parts of the world that now have both Systems installed and treating patients include Tokyo's Metropolitan Center and Infectious Diseases Center Komagome Hospital and Italy's Istituto Europeo di Oncologia.

"The CyberKnife and TomoTherapy Systems enable centers across the world to treat a broad spectrum of patients," said Prof. Eric Lartigau, M.D., PhD, head of academic radiotherapy at Centre Oscar Lambret in Lille, France and president of Accuray Exchange in Radiation Oncology (AERO). "The CyberKnife System is an ideal treatment for many patients with early-stage or localized tumors, while TomoTherapy offers unparalleled benefits for more advanced-stage, complex tumors."

"This emerging trend of medical centers investing in both Accuray's CyberKnife and TomoTherapy Systems illustrates community-wide recognition of the complimentary relationship of our innovative product offerings," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "Our customers are proving that adoption of Accuray's versatile systems provides comprehensive treatment solutions that serve the full spectrum of radiation oncology patients."

Click here for more information on Swedish Medical Center's use of both systems.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 598 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to range of patient treatments, adoption of technology, and clinical benefits are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, market acceptance of products, clinical applications, and clinical effectiveness and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year, our form 10-Q filed on November 8, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray Incorporated